Abstract
Cervical dystonia (CD) is the most common form of focal dystonia treated with botulinum toxin (BoNT) injections. BoNT has been shown in numerous clinical trials to correct the abnormal posture and movement and to markedly reduce pain associated with CD. In addition, BoNT has favorably modified the natural history of the disease by preventing contractures and other complications of CD, such as secondary degenerative changes of the cervical spine and associated radiculopathy. In a long-term follow-up of patients treated for up to 20 years, the duration of response appears to be sustained and the risk of immunoresistance due to blocking antibodies is relatively small. This review provides and update on the treatment of CD with BoNT type A (BOTOX®, Dysport®, Xeomin®) and BoNT type B (Myobloc™, NeuroBloc®).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benecke R, WH Jost, P Kanovsky, E Ruzicka, G Comes and S Grafe (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.Neurology 64, 1949–1951.
Berman B, L Seeberger and R Kumar (2005) Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.Mov. Disord. 20, 233–237.
Comella CL, J Jankovic, S Daggett, J Mordaunt and MF Brin (2004) Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.Neurology 62 (Suppl. 5), A511.
Comella CL, J Jankovic, KM Shannon, J Tsui, M Swenson, S Leurgans and W Fan Dystonia Study Group (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 65, 1423–1429.
Consky ES and AE Lang (1994) Clinical assessments of patients with cervical dystonia, In:Therapy with Botulinum Toxin (Jankovic J and M Hallett, Eds.) (Marcel Dekker: New York, NY),pp 211–237.
Diamond A, J Shahed, S Azher, K Dat-Vuong, R Simpson and J Jankovic (2005) Globus pallidus deep brain stimulation in dystonia.Mov. Disord. 2005 Dec 9; [Epub ahead of print].
Dressler D and R Benecke (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.Eur. Neurol. 49, 34–38.
Dressler D and H Bigalke (2005) Botulinum toxin type Bde novo therapy of cervical dystonia: frequency of antibody induced therapy failure.J. Neurol. 252, 904–907.
Dressler D, M Lange and H Bigalke (2005) Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.Mov. Disord. 20, 1617–1619.
Ertekin C, I Aydogdu, Y Secil, N Kiylioglu, S Tarlaci and T Ozdemirkiran (2002) Oropharyngeal swallowing in craniocervi-cal dystonia.J. Neurol. Neurosurg. Psychiatry 73, 406–411.
Factor SA, ES Molho, S Evans and PJ Feustel (2005) Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.Mov. Disord. 20, 1152–1160.
Jankovic J (2004a) Treatment of cervical dystonia with botulinum toxin.Mov. Disord. 19 (Suppl. 8), S109A-S115A.
Jankovic J (2004b) Botulinum toxin in clinical practice.J. Neurol. Neurosurg. Psychiatry 75, 951b-957b.
Jankovic J, KD Vuong and J Ahsan (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology 60, 1186–1188.
Jankovic J, A Esquenazi, D Fehling, F Freitag, AM Lang and M Naumann (2004) Evidence-based review of patient reported outcomes with botulinum toxin type A.Clin. Neuropharmacol. 27, 234–244.
Jankovic J, J Tsui and C Bergeron (2005a) Prevalence of cervical dystonia and spasmodic torticollis in the United States.Mov. Disord. 20 (Suppl. 10) S22a.
Jankovic J, CB Hunter and the BOS Study Group (2005b) Botulinum toxin type B observational study.Ann. Neurol. 58 (Suppl. 9) S54.
Marchetti A, R Magar, L Findley, JP Larsen, Z Pirtosek, E Ruzicka, R Jech, J Slawek and F Ahmed (2005) Retrospective evaluation of the dose of Dysport® and BOTOX® in the management of cervical dystonia and blepharospasm: The REAL DOSE study.Mov. Disord. 20, 937–944.
Mejia NI, KD Vuong and J Jankovic (2005) Long-term botulinum toxin efficacy, safety and immunogenicity.Mov. Disord. 20, 592–597.
Naumann M and J Jankovic (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis.Curr. Med. Res. Opin. 20, 981–990.
Riski JE, J Horner and BS Nashold Jr (1990) Swallowing function in patients with spasmodic torticollis.Neurology 40, 1443–1445.
Tintner R, R Gross, UF Winzer, KA Smalky and J Jankovic (2005) Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.Neurology 65, 765–767.
Truong D, DD Duane, J Jankovic, C Singer, LC Seeberger, CL Comella, MF Lew, RL Rodnitzky, FO Danisi, JP Sutton, PD Charles, RA Hauser and GL Sheean (2005) Efficacy and safety of botulinum type A toxin (Dysport®) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.Mov. Disord. 20, 783–791.
Vidailhet M, L Vercueil, JL Houeto, P Krystkowiak, AL Benabid, P Cornu, C Lagrange, S Tezenas du Montcel, D Dormont, S Grand, S Blond, O Detante, B Pillon, C Ardouin, Y Agid, A Destee, P Pollak and the French Stimulation du Pallidum Interne dans la Dystonie (SPIDY) Study Group (2005) Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia.N. Engl. J. Med. 352, 459–467.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jankovic, J. Botulinum toxin therapy for cervical dystonia. neurotox res 9, 145–148 (2006). https://doi.org/10.1007/BF03033933
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03033933